Navigation Links
Neurotherapeutics presents special issue on new treatments for Alzheimer's disease
Date:7/24/2008

Chicago, 24 July 2008 The editors of Neurotherapeutics are pleased and proud to announce their July issue, devoted to "Novel Therapeutics for Alzheimer's Disease." Neurotherapeutics (http://www.neurotherapeutics.org/) is the journal of the American Society of Experimental NeuroTherapeutics (ASENT) www.asent.org.

The issue coincides with the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD), being held at McCormick Place, Chicago, July 26 to 31, 2008. Rudolph E. Tanzi, Ph.D., of the Massachusetts General Institute for Neurodegenerative Disease and Massachusetts General Hospital, is a Guest Editor. "In this issue of Neurotherapeutics, we have enlisted several experts in the field to review the most promising new therapeutics currently under development for the treatment and prevention of AD," Dr. Tanzi writes in the introductory editorial.

The eleven papers in the special issue highlight promising therapeutic targets for Alzheimer's disease, providing an update on efforts to develop treatments. Given the central role of amyloid β peptide (Aβ) in the pathogenesis of Alzheimer's disease, cerebral accumulations of Aβ are a major focus. The lead article in the issue looks at techniques for measuring the effects of disease-modifying therapies on cerebral Aβ levelsincluding the key question of whether they correlate with cognitive performance.

Clinical trials aimed at all of these therapeutic targets are underway. In his editorial, Dr. Tanzi expresses "cautious optimism and high hopes" that these trials may lead to new therapeutic approaches to Alzheimer's disease. He concludes, "With several active clinical trials and other promising drugs now headed toward the clinic, the hope is that we will soon have novel AD therapeutics that successfully slow or reverse disease progress in AD."


'/>"/>

Contact: Caroline Foote
c.foote@elsevier.com
215-239-3653
Elsevier
Source:Eurekalert

Related medicine news :

1. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
2. Vertos Medical Inc. Presents Clinical Data of its MILD™ Procedure at the 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos, Mexico
3. Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
4. ExonHit Presents Therapeutic and Diagnostic Programs for Alzheimers at ICAD 2008
5. OptiNose presents data on highly effective migraine treatment
6. International Association for Dental Research presents awards and fellowships
7. MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alexs Lemonade Stand Foundation
8. Journal STEM CELLS Presents 3rd Annual Young Investigator Award at International Stem Cell Symposium
9. The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation
10. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
11. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: